ClinicalTrials.gg
CompletedNCT02902965Updated Mar 16, 2020Results posted

Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma

A Phase 2 interventional study of Ibrutinib and Bortezomib in Multiple Myeloma, sponsored by Pharmacyclics Switzerland GmbH. Completed at 33 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-16.

Sponsored by Pharmacyclics Switzerland GmbH (part of AbbVie) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
74
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 271 studies testing bortezomib in Multiple Myeloma — 12 open to participants now, 40 under way, 14 of them phase 3. Bortezomib · Multiple Myeloma.

Enrollment
70th of 267
74 · median 41
Started
2016
with 8 others
Phase 2
137 of 271
6 open now
Registered
216th of 271
by date

Among the 271 studies testing bortezomib in Multiple Myeloma, this one is the 70th largest by enrollment of the 267 interventional ones that give a count, is one of 9 that started in 2016, is one of 137 in phase 2, and was the 216th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

12 of the 271 studies testing bortezomib in Multiple Myeloma are open now, in 10 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About bortezomib

Bortezomib: first FDA approval 2003 (VELCADE), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 271 studies testing bortezomib in Multiple Myeloma, or all of them as a file.
02

Study summary

This is a Phase 2 open-label study to evaluate the efficacy and safety of ibrutinib in combination with bortezomib and dexamethasone for patients with relapsed or relapsed and refractory multiple myeloma.

Read the detailed description

Bruton's tyrosine kinase (Btk) is an enzyme that is present in hematopoeitic cells other than T cells and is necessary for downstream signal transduction from various hematopoietic receptors including the B cell receptor as well as some Fc, chemokine and adhesion receptors, and is crucial for both B cell development and osteoclastogenesis. Although down-regulated in normal plasma cells, Btk is highly expressed in the malignant cells from many myeloma patients and some cell lines. Ibrutinib is a potent and specific inhibitor of Btk currently in Phase 2 and 3 clinical trials. The current study is designed and intended to determine the safety and efficacy of ibrutinib in combination with bortezomib and dexamethasone in subjects with relapsed/relapsed and refractory multiple myeloma.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Bruton's Tyrosine Kinase
  • Bortezomib
  • Dexamethasone
  • Ibrutinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with multiple myeloma (MM) who have received 1-3 and have demonstrated disease progression since the completion of the most recent treatment regimen. (Subjects may have received prior bortezomib exposure if it does not meet the exclusion criteria for prior proteasome inhibitor use)
  • defined by at least one of the following:

    • Serum monoclonal protein (SPEP) ≥1 g/dL (for subjects with immunoglobulin A (IgA), immunoglobulin D (IgD), immunoglobulin E (IgE) or immunoglobulin M (IgM) multiple myeloma SPEP ≥0.5 g/dL)
    • Urine monoclonal protein (UPEP) ≥200 mg by 24 hour urine electrophoresis
  • Adequate hematologic, hepatic and renal function
  • (ECOG) performance status of ≤2

Exclusion criteria

Exclusion Criteria:

  • Subject must not have primary disease
  • Refractory or non-responsive to prior proteasome inhibitor (PI) therapy (bortezomib or carfilzomib)
  • Peripheral neuropathy Grade ≥2 or Grade 1 with pain at Screening
  • Plasma cell leukemia, primary amyloidosis, or POEMS syndrome
  • Unable to swallow capsules or disease significantly affecting gastrointestinal function
  • Requires treatment with strong inhibitors
  • Women who are pregnant or breast feeding
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    Ibrutinib+ Bortezomib+ Dexamethasone

    Drug: Ibrutinib · Drug: Bortezomib · Drug: Dexamethasone

Interventions

  • Ibrutinib 840 mg orally, once daily continuously starting day 1 of cycle 1 until confirmed disease progression, unacceptable toxicity or other protocol specified reason for discontinuation

    Also known as: Imbruvica

  • Cycles 1-8: (21-day cycle): Bortezomib 1.3 mg/m\^2 sub-cutaneously on days 1, 4, 8, and 11 of each Cycle Cycles 9-12: (42-day cycle): Bortezomib 1.3 mg/m\^2 sub-cutaneously on days 1, 8, 22 and 29 of each Cycle

    Also known as: Velcade

  • Cycles 1-8: (21-day cycle): Dexamethasone 20 mg orally on days 1, 2, 4, 5, 8, 9, 11 and 12 of each cycle Cycles 9-12: (42-day cycle): Dexamethasone 20 mg orally on days 1, 2, 8, 9, 22, 23, 29 and 30 of each cycle Cycles 13+ (28-day cycle): Dexamethasone 40 mg orally once weekly Dose adjustment of dexamethasone to 10 mg on days specified during cycles 1-12 and 20 mg weekly during cycles 13+ is recommended for subjects \>75 years of age. Following implementation of Protocol Amendment 4, dexamethasone administration was reduced to Days 1, 4, 8 and 11 during each 21-day cycle (Cycles 1-8) and on Days 1, 8, 22, 29 on each 42-day cycle (Cycles 9-12) and unchanged thereafter.

06

What researchers measure

Primary outcomes

  1. Median Progression-Free Survival (PFS)

    The primary efficacy endpoint of this study is mPFS. Progression free survival is defined as the time from the date of first dose of study treatment to confirmed disease progression or death from any cause, whichever occurs first.

    Time frame: The median time on study was 19.6 months (range: 0.16+, 24.64). Participants were evaluated for Progression-Free Survival (PFS) during their entire time on the study.

Secondary outcomes

  1. Overall Response Rate (ORR)

    Overall Response Rate is the percentage of participants who achieve a PR or better over the course of the study but prior to initiation of subsequent anti-cancer therapy

    Time frame: The median time on study was 19.6 months (range: 0.16+, 24.64). Participants were evaluated for Overall Response (OR) during the entire time on the study.

  2. Progression Free Survival (PFS) at Landmark Points - 20 Months

    PFS at landmark points are the percentage of participants without progression (i.e., KM estimates) at the landmark time endpoints.

    Time frame: The median time on study was 19.6 months (range: 0.16+, 24.64), with the 20 month Progression-Free Survival (PFS) rate presented based on Kaplan-Meier estimates.

  3. Duration of Response (DOR)

    The time interval between the date of initial documentation of a response (PR or better) and the date of first documented evidence of PD, death, or date of censoring for the participants not progressed/died. The censoring date is the last adequate tumor assessment date.

    Time frame: The median time on study was 19.6 months (range: 0.16+, 24.64).

  4. Overall Survival (OS) at 24 Months

    As the median overall survival has not been reached, the data for the landmark analysis at 24 months are provided.

    Time frame: The median time on study was 19.6 months (0.16+, 24.64), with the 24 month Overall Survival (OS) rate presented based on Kaplan-Meier estimates.

  5. Time to Progression (TTP)

    Time from date of first dose of study treatment to the date of first documented evidence of PD or date of censoring for the participants not progressed. The censoring date is the last adequate tumor assessment date.

    Time frame: The median time on study was 19.6 months (range: 0.16+, 24.64).

  6. Safety and Tolerability of Ibrutinib in Combination With Bortezomib and Dexamethasone as Measured by the Number of Participants With Adverse Events.

    Safety and tolerability of ibrutinib in combination with bortezomib and dexamethasone as measured by the frequency and type of adverse events graded using the NCI CTCAE v 4.03. Frequency and Type of Adverse Events are reported in the Adverse Events module

    Time frame: From first dose of Ibrutinib to within 30 days of last dose for each participant or until study closure. This is the median treatment duration for Ibrutinib of 5.7 months (range: 0.1 - 23.7 months) +30 days (Adverse Events collection period).

07

Results

Posted Jan 2, 2020

Participant flow

Participant flow — Overall Study
MilestoneIbrutinib+ Bortezomib+ Dexamethasone
Started74
Completed64
Not completed10
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryMedian Progression-Free Survival (PFS)

The primary efficacy endpoint of this study is mPFS. Progression free survival is defined as the time from the date of first dose of study treatment to confirmed disease progression or death from any cause, whichever occurs first.

Time frame:
The median time on study was 19.6 months (range: 0.16+, 24.64). Participants were evaluated for Progression-Free Survival (PFS) during their entire time on the study.
Reported as:
Median · Months
Median Progression-Free Survival (PFS)
MonthsIbrutinib+ Bortezomib+ Dexamethasone
Median Progression-Free Survival (PFS)8.5 (6.2 to 10.8)
Statistical analysis
  • Ibrutinib+ Bortezomib+ Dexamethasone · Median pfs: 8.5 · 95% CI 6.2 to 10.8Kaplan-Meier estimates for median PFS and its associated 95% confidence intervals using log-log transformed Greenwood variance estimate were calculated.
SecondaryOverall Response Rate (ORR)

Overall Response Rate is the percentage of participants who achieve a PR or better over the course of the study but prior to initiation of subsequent anti-cancer therapy

Time frame:
The median time on study was 19.6 months (range: 0.16+, 24.64). Participants were evaluated for Overall Response (OR) during the entire time on the study.
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsIbrutinib+ Bortezomib+ Dexamethasone
Overall Response Rate (ORR)56.8 (44.7 to 68.2)
Statistical analysis
  • Ibrutinib+ Bortezomib+ Dexamethasone · Orr in %: 56.8 · 95% CI 44.7 to 68.2Overall response = confirmed sCR + CR + VGPR + PR with corresponding 95% Exact binomial Cl
SecondaryProgression Free Survival (PFS) at Landmark Points - 20 Months

PFS at landmark points are the percentage of participants without progression (i.e., KM estimates) at the landmark time endpoints.

Time frame:
The median time on study was 19.6 months (range: 0.16+, 24.64), with the 20 month Progression-Free Survival (PFS) rate presented based on Kaplan-Meier estimates.
Reported as:
Number · percentage of participants
Progression Free Survival (PFS) at Landmark Points - 20 Months
percentage of participantsIbrutinib+ Bortezomib+ Dexamethasone
Progression Free Survival (PFS) at Landmark Points - 20 Months6.6 (1.6 to 16.9)
Statistical analysis
  • Ibrutinib+ Bortezomib+ Dexamethasone · Pfs rate: 6.6 · 95% CI 1.6 to 16.9Kaplan-Meier method used for PFS rate and its associated 95% confidence intervals using log-log transformed Greenwood variance estimate were calculated.
SecondaryDuration of Response (DOR)

The time interval between the date of initial documentation of a response (PR or better) and the date of first documented evidence of PD, death, or date of censoring for the participants not progressed/died. The censoring date is the last adequate tumor assessment date.

Time frame:
The median time on study was 19.6 months (range: 0.16+, 24.64).
Reported as:
Median · Months
Duration of Response (DOR)
MonthsIbrutinib+ Bortezomib+ Dexamethasone
Duration of Response (DOR)9.5 (6.9 to 10.6)
SecondaryOverall Survival (OS) at 24 Months

As the median overall survival has not been reached, the data for the landmark analysis at 24 months are provided.

Time frame:
The median time on study was 19.6 months (0.16+, 24.64), with the 24 month Overall Survival (OS) rate presented based on Kaplan-Meier estimates.
Reported as:
Number · percentage of participants
Overall Survival (OS) at 24 Months
percentage of participantsIbrutinib+ Bortezomib+ Dexamethasone
Overall Survival (OS) at 24 Months53.6 (38.0 to 67.0)
SecondaryTime to Progression (TTP)

Time from date of first dose of study treatment to the date of first documented evidence of PD or date of censoring for the participants not progressed. The censoring date is the last adequate tumor assessment date.

Time frame:
The median time on study was 19.6 months (range: 0.16+, 24.64).
Reported as:
Median · Months
Time to Progression (TTP)
MonthsIbrutinib+ Bortezomib+ Dexamethasone
Time to Progression (TTP)10.6 (7.8 to 12)
Statistical analysis
  • Ibrutinib+ Bortezomib+ Dexamethasone · Median ttp: 10.6 · 95% CI 7.8 to 12KM estimates for median TTP with associated 95% CI
SecondarySafety and Tolerability of Ibrutinib in Combination With Bortezomib and Dexamethasone as Measured by the Number of Participants With Adverse Events.

Safety and tolerability of ibrutinib in combination with bortezomib and dexamethasone as measured by the frequency and type of adverse events graded using the NCI CTCAE v 4.03. Frequency and Type of Adverse Events are reported in the Adverse Events module

Time frame:
From first dose of Ibrutinib to within 30 days of last dose for each participant or until study closure. This is the median treatment duration for Ibrutinib of 5.7 months (range: 0.1 - 23.7 months) +30 days (Adverse Events collection period).
Reported as:
Count of participants · Participants
Safety and Tolerability of Ibrutinib in Combination With Bortezomib and Dexamethasone as Measured by the Number of Participants With Adverse Events.
ParticipantsIbrutinib+ Bortezomib+ Dexamethasone
Safety and Tolerability of Ibrutinib in Combination With Bortezomib and Dexamethasone as Measured by the Number of Participants With Adverse Events.74

Adverse events

Collected over From first dose of Ibrutinib to within 30 days of last dose for each participant or until study closure. This is the median treatment duration for Ibrutinib of 5.7 months (range: 0.1 - 23.7 months) +30 days (Adverse Events collection period).. Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ibrutinib+ Bortezomib+ Dexamethasone27/74 (36.5%)47/74 (63.5%)74/74 (100%)
Most frequent serious events
Showing 10 of 66
Most frequent serious events
EventIbrutinib+ Bortezomib+ Dexamethasone
PneumoniaInfections and infestations11/74
Atrial fibrillationCardiac disorders3/74
SepsisInfections and infestations3/74
Spontaneous haematomaBlood and lymphatic system disorders3/74
ThrombocytopeniaBlood and lymphatic system disorders2/74
Renal failureRenal and urinary disorders2/74
HyponatraemiaMetabolism and nutrition disorders2/74
BronchitisInfections and infestations2/74
Lung infectionInfections and infestations2/74
Pneumonia bacterialInfections and infestations2/74
Most frequent other events
Showing 10 of 75
Most frequent other events
EventIbrutinib+ Bortezomib+ Dexamethasone
ThrombocytopeniaBlood and lymphatic system disorders45/74
DiarrhoeaGastrointestinal disorders40/74
AnaemiaBlood and lymphatic system disorders28/74
AstheniaGeneral disorders22/74
FatigueGeneral disorders21/74
Oedema peripheralGeneral disorders21/74
Upper respiratory tract infectionInfections and infestations19/74
Periperal sensory neuropathyNervous system disorders18/74
NauseaGastrointestinal disorders18/74
CoughRespiratory, thoracic and mediastinal disorders15/74

Baseline characteristics

All participant received: see description on Arm/Group description.

Age, Categorical
Age, Categorical(Participants)Ibrutinib+ Bortezomib+ Dexamethasone
<=18 years0
Between 18 and 65 years29
>=65 years45
Age, Continuous
Age, Continuous(years)Ibrutinib+ Bortezomib+ Dexamethasone
Mean65.9 ± 10.14
Sex: Female, Male
Sex: Female, Male(Participants)Ibrutinib+ Bortezomib+ Dexamethasone
Female39
Male35
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ibrutinib+ Bortezomib+ Dexamethasone
Hispanic or Latino2
Not Hispanic or Latino68
Unknown or Not Reported4
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ibrutinib+ Bortezomib+ Dexamethasone
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White71
More than one race0
Unknown or Not Reported3
Region of Enrollment
Region of Enrollment(participants)Ibrutinib+ Bortezomib+ Dexamethasone
Greece11
Turkey13
Czechia23
Italy10
Germany1
Spain16
08

Study locations

33 sites
  • Fakultní nemocnice Brno
    Brno, Czechia
  • Fakultní nemocnice Hradec Králové
    Nový Hradec Králové, Czechia
  • Fakultní nemocnice Ostrava
    Ostrava-Poruba, Czechia
  • Všeobecná fakultní nemocnice v Praha
    Praha 2, Czechia
  • Helios-Kliniken Berlin-Buch
    Berlin, Germany
  • Vivantes Klinikum Spandau
    Berlin, Germany
  • Universitätsklinikum Jena
    Jena, Germany
  • Klinikum der Universität München Campus Grosshadern
    München, Germany
  • 251 General Air Force Hospital
    Athens, Greece
  • General Hospital of Athens "Alexandra"
    Athens, Greece
  • General Hospital of Athens "Evangelismos"
    Athens, Greece
  • General Hospital of Athens "LAIKO"
    Athens, Greece
  • University General Hospital of Patra
    Patras, Greece
  • General Hospital of Thessaloniki "G. Papanikolau"
    Thessaloniki, Greece
  • IRCCS Ospedale Casa Sollievo della Sofferenza
    San Giovanni Rotondo, Foggia, Italy
  • Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi
    Bologna, Italy
  • Istituto Scientifico Romagnolo Per lo Studio e la Cura dei Tumori
    Meldola (FC), Italy
  • Ospedale Santa Maria delle Croci
    Ravenna, Italy
  • Ospedale degli Infermi
    Rimini, Italy
  • Azienda Ospedaliera S. Maria di Terni
    Terni, Italy
  • Hospital Universitario Rey Juan Carlos
    Mostoles, Madrid, Spain
  • Complejo Hospitalario Universitario A Coruña
    A Coruna, Spain
  • ICO Badalona-Hospital Germans Trias i Pujol
    Badalona, Spain
  • Hospital Clínic i Provincial de Barcelona
    Barcelona, Spain
  • Hospital Universitario Madrid Sanchinarro
    Madrid, Spain
  • Clinica Universidad de Navarra
    Pamplona, Spain
  • Hospital Universitario de Salamanca
    Salamanca, Spain
  • Hospital Universitario Virgen del Rocio
    Sevilla, Spain
  • Hospital Universitario Dr. Peset
    Valencia, Spain
  • Ankara University Medical Faculty
    Ankara, Turkey
  • Dokuz Eylul University Medicine Faculty
    Izmir, Turkey
  • Erciyes University Medical Faculty
    Kayseri, Turkey
  • Ondokuz Mayis Univ. Med. Fac.
    Samsun, Turkey
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2016 to primary completion in Oct 2018, 25 months.

Results were first posted in Jan 2020, 1 year 2 months after primary completion.

Of 93 industry-sponsored phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 77. This study's 25 months is below that.

Counting every sponsor, half of 506 studies reached it within 57 months; a quarter within 35 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2016
First posted
Sep 16, 2016
StartActual
Sep 20, 2016
Primary completionActual
Oct 26, 2018
CompletionActual
Oct 26, 2018
Results first posted
Jan 2, 2020
Last update
Mar 16, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02902965
Responsible party
Sponsor
First posted
Sep 16, 2016
Start date
Sep 20, 2016
Primary completion
Oct 26, 2018
Completion
Oct 26, 2018
Results posted
Jan 2, 2020
Last update
Mar 16, 2020

Study contacts

Bernhard Hauns, MD
study director · Pharmacyclics Switzerland GmbH

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ibrutinib · Bortezomib · Dexamethasone

Start the discussion